209 related articles for article (PubMed ID: 21979593)
1. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53.
Brunner AH; Riss P; Heinze G; Meltzow E; Brustmann H
Int J Gynecol Pathol; 2011 Nov; 30(6):569-75. PubMed ID: 21979593
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
4. Expression of γ-H2AX in endometrial carcinomas: an immunohistochemical study with p53.
Brunner AH; Hinterholzer S; Riss P; Heinze G; Weiss K; Brustmann H
Gynecol Oncol; 2011 Apr; 121(1):206-11. PubMed ID: 21185067
[TBL] [Abstract][Full Text] [Related]
5. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study.
Salvesen HB; Iversen OE; Akslen LA
J Clin Oncol; 1999 May; 17(5):1382-90. PubMed ID: 10334522
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
8. SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas.
Kihara A; Wakana K; Kubota T; Kitagawa M
Histopathology; 2016 Sep; 69(3):374-82. PubMed ID: 27003026
[TBL] [Abstract][Full Text] [Related]
9. P53 and BCL-2 as prognostic markers in endometrial carcinoma.
Appel ML; Edelweiss MI; Fleck J; Rivero LF; Rivoire WA; Mônego HI; Dos Reis R
Pathol Oncol Res; 2008 Mar; 14(1):23-30. PubMed ID: 18398703
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
[TBL] [Abstract][Full Text] [Related]
11. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
13. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma.
Osmanağaoğlu MA; Kadioğlu S; Osmanağaoğlu S; Bozkaya H; Reis A; Tekelioğlu Y
Eur J Gynaecol Oncol; 2005; 26(1):64-70. PubMed ID: 15755004
[TBL] [Abstract][Full Text] [Related]
14. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
Segawa T; Sasagawa T; Saijoh K; Inoue M
Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
17. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
18. Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer.
Li L; Xu DB; Zhao XL; Hao TY
Arch Gynecol Obstet; 2013 Jul; 288(1):155-65. PubMed ID: 23334889
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.
Fadare O; Gwin K; Desouki MM; Crispens MA; Jones HW; Khabele D; Liang SX; Zheng W; Mohammed K; Hecht JL; Parkash V
Mod Pathol; 2013 Aug; 26(8):1101-10. PubMed ID: 23524907
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Soong R; Knowles S; Williams KE; Hammond IG; Wysocki SJ; Iacopetta BJ
Br J Cancer; 1996 Aug; 74(4):562-7. PubMed ID: 8761370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
